Cover Image
市場調查報告書

絲胺酸蛋白激酶 ATM:開發中產品分析

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 516020
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
絲胺酸蛋白激酶 ATM:開發中產品分析 Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 28 Pages
簡介

本報告提供以絲胺酸蛋白激酶ATM為標的之治療藥開發相關資訊,提供開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

絲胺酸蛋白激酶 ATM;概要

絲胺酸蛋白激酶 ATM;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AstraZeneca Plc
  • InteRNA Technologies BV
  • Shuttle Pharmaceuticals LLC

藥物簡介

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

目錄
Product Code: GMDHC0829TDB

Summary

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Serine Protein Kinase ATM - Pipeline Review, H1 2017, outlays comprehensive information on the Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Serine Protein Kinase ATM is a serine/threonine protein kinase. It activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. It plays a role in replication-dependent histone mRNA degradation. It binds DNA ends. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology and Toxicology which include indications Adenocarcinoma, Breast Cancer, Colon Cancer, Colorectal Cancer, Gastric Cancer, Head And Neck Cancer, Herpetic Keratitis, Metastatic Cancer, Multiple Myeloma (Kahler Disease), Radiation Toxicity (Radiation Sickness and Acute Radiation Syndrome).

Furthermore, this report also reviewsalso reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
  • The report reviews Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Overview
    • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • InteRNA Technologies BV
    • Shuttle Pharmaceuticals LLC
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit Mutated Ataxia Telangiectasia Gene for Head and Neck Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-0156 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KU-55933 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KU-59403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-1161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: AstraZeneca Presents Data On Next-generation Investigational ATM Inhibitor at the AACR 2016 Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by AstraZeneca Plc, H1 2017
  • Pipeline by InteRNA Technologies BV, H1 2017
  • Pipeline by Shuttle Pharmaceuticals LLC, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top